GlassScriptPhysician profile
Sandra Walker Nichols
NPI 1770749202
$4,768.67
in general payments reported to CMS, 2019-2025
22 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $1,269 · 2023: $1,628 · 2024: $883 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,252.63 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,210.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $694.47 | 2022-2025 | Spravato |
| Neurocrine Biosciences, INC. | $329.39 | 2022-2025 | Ingrezza |
| Eisai INC. | $188.52 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.12 | 2023-2025 | Caplyta |
| Corium, LLC | $156.53 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $155.63 | 2022-2025 | Trintellix, Entyvio |
| Lundbeck LLC | $116.10 | 2022-2025 | Rexulti |
| Sage Therapeutics, LLC | $106.50 | 2023 | |
| Spark Therapeutics, INC. | $78.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $62.91 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $49.26 | 2023-2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $33.78 | 2024 | Wegovy |
| Avanir Pharmaceuticals, INC. | $28.33 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $23.45 | 2025 | |
| Tris Pharma INC | $22.57 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $19.17 | 2025 | Jornay Pm |
| Lilly USA, LLC | $19.10 | 2025 | Zepbound |
| Astellas Pharma US INC | $16.00 | 2025 | Veozah |
| Indivior INC. | $15.91 | 2024 | Sublocade |
| Neos Therapeutics, LP | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.